Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Operating Leases: 2020-2024

Historic Operating Leases for Revolution Medicines (RVMD) over the last 5 years, with Dec 2024 value amounting to $123.0 million.

  • Revolution Medicines' Operating Leases rose 81.50% to $142.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $142.1 million, marking a year-over-year increase of 81.50%. This contributed to the annual value of $123.0 million for FY2024, which is 52.62% up from last year.
  • Per Revolution Medicines' latest filing, its Operating Leases stood at $123.0 million for FY2024, which was up 52.62% from $80.6 million recorded in FY2023.
  • Revolution Medicines' Operating Leases' 5-year high stood at $123.0 million during FY2024, with a 5-year trough of $29.0 million in FY2020.
  • For the 3-year period, Revolution Medicines' Operating Leases averaged around $87.0 million, with its median value being $80.6 million (2023).
  • In the last 5 years, Revolution Medicines' Operating Leases spiked by 108.40% in 2021 and then declined by 4.94% in 2022.
  • Over the past 5 years, Revolution Medicines' Operating Leases (Yearly) stood at $29.0 million in 2020, then spiked by 108.40% to $60.4 million in 2021, then declined by 4.94% to $57.4 million in 2022, then soared by 40.30% to $80.6 million in 2023, then soared by 52.62% to $123.0 million in 2024.